Norman Paradis, MD joins Oran Diagnostics as Acting Chief Medical Officer

BERWYN, PA, NOVEMBER 15TH, 2010—Oran Diagnostics, LLC, a specialized medical device company developing novel clinical diagnostic tools for applications across a broad spectrum of disease states, today announced that Norman A. Paradis, MD has joined the Company as Acting Chief Medical Officer. Dr. Paradis will be responsible for providing the Company guidance in clinical trial design, regulatory submissions, new product development and product strategy and positioning.

Dr. Paradis is a recognized leader in the medical device and molecular diagnostics arena. He has led medical, clinical and research teams working in both diagnostics and therapeutics; including biomarkers, cardiovascular devices, ischemia-reperfusion, and sepsis, and immunodiagnostics. Dr. Paradis’ experience makes him exceptionally well suited to assist in the development and commercialization of the TCL Analyzer ™, Oran’s innovative platform technology with potential applications across multiple clinical specialties. Dr. Paradis was previously Vice-President of Clinical and Medical Affairs at Biosite Inc. (now Inverness), where he built teams that designed and initiated more than a dozen clinical trials in molecular biomarkers. Subsequently he served as Vice President and Chief Medical Officer at Cylex Inc.

Prior to entering the private sector, Dr. Paradis served as Professor of surgery and medicine at the University of Colorado, and Senior Medical Director of emergency medicine at University of Colorado Hospital from 1999 to 2005, where he headed a research group with active programs in real-time diagnostic technology, hemodynamics, hypothermia, stroke biomarkers, fibrinolytics and emergency cardiopulmonary bypass. He is an acting Co-Director of the Colorado Emergency Medicine Research Center. Dr. Paradis has also held clinical, academic and administrative positions at Columbia University, New York University and Medical College of Virginia. He has been a member of numerous medical professional organizations, including the Society for Academic Emergency Medicine (SAEM), Society of Critical Care Medicine (SCCM), the American College of Emergency Medicine (ACEP), and the American Academy of Emergency Medicine (AAEM) among others. Dr. Paradis was one of the founding members of SAEM's Reperfusion Working Group, and has been active in the American Heart Association (AHA), serving on the Advanced Cardiac Life Support (ACLS) Subcommittee for more than 10 years. He is also a fellow of the American Board of Emergency Medicine. Dr. Paradis is on the editorial boards of The American Journal of Emergency Medicine, Resuscitation, and the Critical Illness section of the Journal of the American Medical Association (JAMA). He has published more than 50 papers in cardiology, critical care and emergency medicine journals as well as being the senior editor of Cardiac Arrest-The Science and Practice of Resuscitation Medicine. Dr. Paradis trained in emergency medicine at the University of Southern California (USC) and completed a research fellowship at Henry Ford Hospital. He received his B.S. with Highest Honors in Molecular Biology from Marlboro College and earned his M.D. from Northwestern University.

About Oran Diagnostics

Oran Diagnostics, LLC is using its proprietary device (the TCL Analyzer ™) and method (thermochemiluminescence) to develop accurate, minimally invasive clinical tools for use in clinical diagnostics, and for drug discovery and development. The company’s proprietary technology is currently being applied in cardiovascular and neurodegenerative disease. Oran Diagnostics is headquartered in Berwyn, PA, with research and development facilities in Haifa, Israel. For more information, please visit www.orandx.com.

TCL-HF™ is a rapid, minimally invasive procedure for designed to aid in the risk stratification of patients diagnosed with heart failure. The TCL Analyzer™ measures lipid peroxidation in a small sample (50 microlitres) of blood serum. Using a highly sensitive, proprietary method of biomarker identification (thermochemiluminescence), TCL-HF™ measures the level of oxidative stress and oxidizability, which measurement correlates with the degree of disease severity. Analysis can be performed in a hospital or clinical laboratory in just minutes. TCL-HF™ provides a relevant, previously unavailable clinical data point that helps guide treatment options for patients with heart failure. The TCL Analyzer™ and TCL-HF™ are not currently cleared for use in the U.S. by the Food and Drug Administration.

Contact: Meredith Hegg
491 Baltimore Pike Suite 209
Springfield, PA 19064
Phone: 610-626-0175

This release was published on openPR.